Market capitalization | $561.88m |
Enterprise Value | $355.21m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.28 |
P/S ratio (TTM) P/S ratio | 2.02 |
P/B ratio (TTM) P/B ratio | 0.49 |
Revenue growth (TTM) Revenue growth | -3.02% |
Revenue (TTM) Revenue | $277.76m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
3 Analysts have issued a Fulgent Genetics forecast:
3 Analysts have issued a Fulgent Genetics forecast:
Sep '24 |
+/-
%
|
||
Revenue | 278 278 |
3%
3%
|
|
Gross Profit | 93 93 |
10%
10%
|
|
EBITDA | -63 -63 |
39%
39%
|
EBIT (Operating Income) EBIT | -89 -89 |
9%
9%
|
Net Profit | -165 -165 |
160%
160%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Fulgent Genetics, Inc. operates as a technology company, which provides genetic testing and next generation sequencing solutions. Its technology platform includes proprietary gene probes, advanced database algorithms, adaptive learning software, and proprietary laboratory information management systems. The company was founded on May 13, 2016 and is headquartered in Temple City, CA.
Head office | United States |
CEO | Ming Hsieh |
Employees | 1,184 |
Founded | 2016 |
Website | www.fulgentgenetics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.